Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 19 June 2018
Indication(s)
- PritorPlus 40 mg/12.5 mg tablets
- PritorPlus 80 mg/12.5 mg tablets
Treatment of essential hypertension.
PritorPlus fixed dose combination (40 mg telmisartan/12.5 mg hydrochlorothiazide and 80 mg telmisartan/12.5 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on telmisartan alone.
- PritorPlus 80 mg/25 mg tablets
Treatment of essential hypertension.
PritorPlus fixed dose combination (80 mg telmisartan/25 mg hydrochlorothiazide) is indicated in adults whose blood pressure is not adequately controlled on PritorPlus 80 mg/12.5 mg (80 mg telmisartan/12.5 mg hydrochlorothiazide) or adults who have been previously stabilised on telmisartan and hydrochlorothiazide given separately.
Learning Zones
An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.
Cardiovascular Metabolism Knowledge Centre
The Cardiovascular Metabolism Knowledge Centre is an information hub providing expert insight into the management of hypertension and type 2 diabetes. This Knowledge Centre contains a wealth of scientific video content offering insights and opinion from some of the leading experts in the field.
Acute and Advanced Heart Failure
What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...
+ 3 more
Migraine Knowledge Centre
The Migraine Knowledge Centre features latest research on the prevalence and impact of migraine, the proposed neurological basis of the condition (and how this is being translated into new and exciting drug therapies), as well as current patient care strategies collated from headache organisations worldwide.
Chronic Obstructive Pulmonary Disease (COPD)
View highlights from recent congresses presented in new expert videos with leading physicians.
+ 7 more
Transplantation
See information on best practice in solid organ transplantation, and expert discussions on related hot topics.
ESICM LIVES Highlights
ESICM LIVES Congress 2018: Bringing you the latest news and insights from the 31st ESICM LIVES Congress, 20–24 October 2018 Paris, France.
Oral Anticoagulation Reversal
Experts discuss the use of non-vitamin K oral anticoagulants in the treatment and prevention of stroke, deep vein thrombosis and pulmonary embolism in atrial fibrillation patients.
Cushing's Syndrome
Cushing’s syndrome shares symptoms such as hypertension, glucose intolerance and obesity with other common conditions – how can you confidently diagnose this rare disorder?
+ 2 more
Related Content
A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety (PRECISION)
The purpose of the study is to show the blood pressure lowering effect of aprocitentan, a new drug, when added to other anti-hypertensive drugs of patients with difficult to control (resistant) high blood pressure (hypertension)...
Added 7 months ago
A Study of the ReCor Medical Paradise System in Clinical Hypertension (RADIANCE-HTN)
RADIANCE-HTN is a randomized, double-blind, sham controlled, 2-cohort study (TRIO and SOLO) designed to demonstrate efficacy and document the safety of the Paradise Renal Denervation System in two distinct populations of hypertensive subjects.
Added 6 months ago
SPYRAL HTN-ON MED Study
The purpose of this study is to obtain an assessment of the efficacy and safety of renal denervation in the presence of three standard antihypertensive medications.
Added 6 months ago
Repetitive Levosimendan Infusion for Patients With Advanced Chronic Heart Failure (LeoDOR)
Repetitive levosimendan infusions for patients with advanced chronic heart failure (LeoDOR) A randomised, double-blind, placebo-controlled multicentre study with parallel group design.
Added 1 day ago
Evaluate the Efficacy and Safety of Short-term Administration of SIMDAX
The purpose of the study is to evaluate the efficacy, safety and tolerability of intravenous infusion of Levosimendan for 24hrs in patients with ADHF who will be hospitalized with ADHF and continue to have symptom of dyspnea at rest...
Added 1 day ago
Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update -2016.
True resistant hypertension must be distinguished from apparent resistant hypertension, of which important causes include medication nonadherence, illicit drug use...
Added 2 years ago
Obesity and prevalence of cardiovascular diseases and prognosis:the obesity paradox updated.
The prevalence and severity of obesity has increased in the United States and most of the Westernized World over recent...
Added 3 years ago
Overview of epidemiology and contribution of obesity to cardiovascular disease.
The prevalence of obesity has increased worldwide and is a source of concern since the negative consequences of obesity start...
Added 5 years ago
2013 ESH/ESC Guidelines for the management of arterial hypertension
The 2013 guidelines on hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC) follow the guidelines jointly issued by the two societies in 2003 and 2007.
Added 5 years ago
KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease
The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease aims to provide guidance on blood pressure management and treatment for...
Added 6 years ago
Hypertension in adults: diagnosis and management
This guideline covers identifying and treating primary hypertension (high blood pressure) in people aged 18 and over.
Added 7 years ago
Joint statement of the European Association for the Study of Obesity and the European Society of Hypertension: obesity and difficult to treat arterial hypertension
Obese patients are prone to arterial hypertension, require more antihypertensive medications, and have an increased risk of treatment-resistant arterial hypertension.
Added 6 years ago
More information
Category | Value |
---|---|
Agency product number | EMEA/H/C/000414 |
Orphan designation | No |
Date First Approved | 22-04-2002 |
Type | Medicinal product subject to medical prescription |
Marketing authorisation holder | Bayer AG |